Ryan Jason

Director Ryan Jason sold 39,222 shares for $4,995,800.61 at GeneDx (WGS), reducing stake by 76.7% on trading day to $129.19 high

Ryan Jason, a Director at GeneDx Holdings, executed 7 separate sales totaling 39,222 shares for $4,995,800.61 on 2025-08-27, reducing his holdings from 51,126 to 11,904 shares (a 76.7% reduction). The sales occurred across a narrow price band ($125.07–$130.01 blended average $127.37), and the current price of $129.19 is at the 52-week high with stock up 52.2% in 30 days and 84.6% in 90 days. Notably, his 5 prior sales at WGS over the past nine months generated all positive 90-day returns (+5.7% to +65.0%), with 0 of 5 being well-timed (all occurred before subsequent gains), suggesting a consistent pattern of selling before further appreciation. Given the company's recent exceptional growth trajectory (90-day +84.6%, annual revenue growth +50.8%) and the outsized valuation (P/E 2583.80), the scale and timing of this sale warrant attention as context for current price trajectory.

Director Ryan Jason sells entire 47,000-share WGS stake across 6 transactions for $3.3M; complete liquidation follows strong stock recovery.

Ryan Jason, a Director, executed 6 separate sales totaling 47,000 shares for $3,316,879.80 on November 19–20, 2024, at prices ranging from $68.36 to $72.26, with a blended average price of $70.57. This represents a complete exit: his post-transaction holdings are 0 shares against pre-transaction holdings of 47,000 shares. The sale occurs within a context of substantial recent stock appreciation: WGS has appreciated 24.7% over the past 30 days and 101.5% over 90 days, and the current price of $72.07 stands near the 52-week high of $84.02 (within 14.2% of that peak). Notably, Jason's prior trades at WGS (two buys on 2023-11-16 and 2023-11-17) each generated strong subsequent returns (90-day returns of +247.4% and +189.4%, respectively), demonstrating successful prior timing at this ticker. However, the company remains unprofitable with net income of $-8.3M in its latest quarter and annual revenue declining 13.7% versus the prior year, whereas the stock's recent momentum appears driven by factors outside recent operating fundamentals. The complete liquidation of a profitable long-term position following sustained price appreciation, combined with deteriorating underlying financial metrics, warrants close examination of the decision rationale.